Page 4 - ப்ராடக்ட் சோதனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ராடக்ட் சோதனை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ராடக்ட் சோதனை Today - Breaking & Trending Today

New England Journal of Medicine publishes exploratory study showing signals of positive ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
New England Journal of Medicine publishes exploratory study showing signals of positive .
COMPASS Pathfinder Ltd.April 15, 2021 GMT
London, UK, April 15, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD).
ADVERTISEMENT
The study was designed and conducted by a research team at Imperial College London, using COMPASS’s COMP360 psilocybin. ....

New York , United States , United Kingdom , City Of , Tracy Cheung , George Goldsmith , Stephen Schultz , Exchange Commission , Imperial College London , Drug Administration , New England Journal , Quick Inventory , Depressive Symptomatology , Montgomery Asberg Depression Rating Scale , Hamilton Depression Rating Scale , Serious Adverse Events , Breakthrough Therapy , Securities Act , Private Securities Litigation Reform Act , Products And Services , Mental Health , Western Europe , Product Testing , Diagnosis And Treatment , Globe Newswire , Medical Research ,

Completion of the Third Clinical Trial - an Important Achievement for Medicortex Finland

Press release content from Business Wire. The AP news staff was not involved in its creation.
Completion of the Third Clinical Trial - an Important Achievement for Medicortex Finland
April 15, 2021 GMT
TURKU, Finland (BUSINESS WIRE) Apr 15, 2021
Medicortex Finland Oy, a biotechnology company developing a breakthrough biomarker-based diagnostic kit for brain injury detection, completed collection of body fluid samples in its third large clinical study. Children and adolescents were recruited who visited the hospital with a suspected mild traumatic brain injury or concussion.
“Collecting the samples in this large clinical trial is a significant achievement for Medicortex, and represents an important step forward in the development of the ProbTBI TM, a diagnostic kit for early detection of head injury” said Dr. Adrian Harel, Chief Executive Officer of Medicortex Finland. “Brain injury is a devastating condition leading to medical complications if not diagno ....

Satakunta Region , Adrian Harel , Chief Executive Officer , Initial Public Offering , Private Placement , Traumatic Brain Injury , Business Wire , Corporate News , Products And Services , Health Care Industry , Head Injuries , Traumatic Brain Injuries , Clinical Trials , Stock Offerings , Western Europe , Product Testing , Initial Public Offerings , Medical Biotechnology Industry , Corporate Stock , Medical Research , தலைமை நிர்வாகி அதிகாரி , ஆரம்ப பொது பிரசாதம் , ப்ரைவேட் வேலை வாய்ப்பு , அதிர்ச்சிகரமான மூளை காயம் , வணிக கம்பி , பெருநிறுவன செய்தி ,

CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to .
CytoDyn Inc.April 15, 2021 GMT
Under Compassionate Special Permit (CSP) in Philippines, CytoDyn is well positioned to generate significant revenues
VANCOUVER, Washington., April 15, 2021 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today it has executed an exclusive supply and distribution agreement with Chiral Pharma Corporation to supply up to 200,000 vials of leronlimab to critically ill COVID-19 patients in the Philippines under CSP authorizations. This agreement will accelerate the delivery of leronlimab upon an expanded authorization under CSP. ....

United States , British Columbia , Michael Mulholland , Nader Pourhassan , Samsung Biologics , Exchange Commission , Chiral Pharma Corporation , Drug Administration , Cytodyn Inc , Under Compassionate Special Permit , Chief Executive Officer , Chiral Pharma , Cytodyn Fast Track , Fast Track , Biologics License Application , Looking Statements , Products And Services , Government Regulations , Coronavirus Pandemic , Product Approvals , Product Testing , Globe Newswire , Pharmaceutical Manufacturing , Health Care Industry , Breast Cancer , Lung Disease ,

airKAVE Portable Air Purifier Now Approved To Combat COVID-19

Press release content from PR Newswire. The AP news staff was not involved in its creation.
airKAVE Portable Air Purifier Now Approved To Combat COVID-19
April 15, 2021 GMT
AIRKAVE PORTABLE AIR PURIFIER NOW APPROVED TO COMBAT COVID-19
LOS ANGELES, April 15, 2021 /PRNewswire/ airKAVE, the world’s most advanced air purification technology, announced today that the airKAVE Portable passed the Characterization of Model AH01 Air Purification Device in Deactivation of Aerosolized SARS-COV-2 test (from MRIGlobal). The test confirms that airKAVE Portable destroys aerosolized SARS-CoV-2 within a fraction of a second as the air passes through the filterless device providing personal protection against the Coronavirus (COVID-19.) Now available in the U.S., airKAVE Portable is the world’s first SARS-CoV-2 portable antiviral air sanitizer that can be taken with you anywhere you go. ....

United States , Hong Kong , Hong Kong International Airport , Hong Kong General , Brett Lieberman , Herman Tsui , Rick Jennings , Rick Tuttle , Department Of Energy , Mass Transit Railway , Hong Kong Power Company , Department Of Defense , Purification Device , Kansas City , Test Device , Hong Kong Air Traffic Control Tower , Plascide Specific Railway Stations , Environment And Nature , Severe Acute Respiratory Syndrome , Products And Services , Covid 19 Pandemic , Pr Newswire , Corporate News , Coronavirus Pandemic , Diseases And Conditions , Product Testing ,

Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
Affimed N.V.April 15, 2021 GMT
AFM13 monotherapy: Reported positive data from the preplanned interim analysis for the registration-directed trial in PTCL
AFM13 combination with NK cells: Announced 100% objective response rate in four response evaluable patients, including 2 complete responses
AFM24 monotherapy: AFM24 (phase 1/2a study) completed cohort 4 and is enrolling and treating patients in cohort 5; expansion cohorts expected to start in the second half of 2021
AFM24 combination with NK cells: IND application cleared by the FDA for the combination of AFM24 with NKGen Biotech’s SNK-01 NK autologous cell therapy ....

United States , New York , Baden Wüberg , Nkmax America , Adi Hoess , Artiva Biotherapeutics , Alexander Fudukidis , Silicon Valley Bank , International Financial Reporting Standards , University Of Texas Md Anderson Cancer Center , Drug Administration , Development Strategy , Exchange Commission , Roivant Sciences , Clinical Stage Program Updates , International Accounting Standards Board , Cancer Center , Lymphoma Response , Immunomodulatory Therapy Criteria , Financial Review , Annual Report , International Accounting Standards , Generally Accepted Accounting Principles , Investor Relations , Products And Services , Ownership Changes ,